Cargando…

P1202: INTENDED USE OF GLUCARPIDASE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND IMPAIRED RENAL FUNCTION – THE VALIDATE STUDY

Detalles Bibliográficos
Autores principales:	Liebig, S., Burock, S., Merz, I., Knörnschild, F., Kießling, P., Kappert, K., Keller, U., Schwartz, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430489/ http://dx.doi.org/10.1097/01.HS9.0000847672.21099.b9

Ejemplares similares

Glucarpidase for Treating Adults with Delayed Methotrexate Elimination Due to Impaired Renal Function: An Economic Simulation Analysis
por: Kala, Jaya, et al.
Publicado: (2023)

Glucarpidase to combat toxic levels of methotrexate in patients
por: Green, Jacalyn M
Publicado: (2012)

Methotrexate toxicity treated with continuous venovenous hemofiltration, leucovorin and glucarpidase
por: Connors, Nicholas J., et al.
Publicado: (2014)

PB2106: REDUCTION OF METHOTREXATE (MTX) LEVELS AFTER GLUCARPIDASE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT RISK OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT WHO RECEIVE HDMTX: PHASE 2
por: De La Fuente, A., et al.
Publicado: (2022)

Physics in Pisa 1202-1938: a survey
por: Barcaro, Umberto, et al.
Publicado: (1987)

miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma
por: Takashima, Yasuo, et al.
Publicado: (2020)

Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy
por: Harms, James, et al.
Publicado: (2017)

MicroRNA-1202 plays a vital role in osteoarthritis via KCNQ1OT1 has-miR-1202-ETS1 regulatory pathway
por: Liu, Changzeng, et al.
Publicado: (2020)

Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance
por: Ramsey, Laura B., et al.
Publicado: (2017)

Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury
por: Heuschkel, Sandra, et al.
Publicado: (2021)

A Dose‐Confirmation Phase 1 Study to Evaluate the Safety and Pharmacology of Glucarpidase in Healthy Volunteers
por: Fukaya, Yutaka, et al.
Publicado: (2021)

A Pediatric Renal Lymphoma Case Presenting with Central Nervous System Findings
por: Baran, Ahmet, et al.
Publicado: (2013)

Central nervous system involvement of primary renal lymphoma with diffuse large B-cell type lymphoma
por: Hu, Rong, et al.
Publicado: (2013)

Primary Central Nervous System Lymphoma
por: Dong, Yan-Hong, et al.
Publicado: (2016)

Primary central nervous system lymphoma
por: Gloghini, Annunziata, et al.
Publicado: (2015)

Primary central nervous system lymphoma
por: Löw, Sarah, et al.
Publicado: (2018)

Rare central nervous system lymphomas
por: Kaji, Furqaan Ahmed, et al.
Publicado: (2022)

Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available
por: Rosales, Alejandra, et al.
Publicado: (2021)

Research on the Damage of the Central Nervous System Lymphoma to the Nervous System
por: Hernandez, Jairo, et al.
Publicado: (2023)

COVD-23. PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, Lauren, et al.
Publicado: (2020)

Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study
por: Schaff, Lauren R., et al.
Publicado: (2022)

PB2136: PLANNED-USE GLUCARPIDASE FOR OUTPATIENT HIGH DOSE METHOTREXATE (HD-MTX) ADMINISTRATION IN PATIENTS WITH CNS LYMPHOMA (CNSL) DURING THE COVID-19 PANDEMIC
por: Schaff, L., et al.
Publicado: (2022)

1202. It’s a Confidence Scheme—Transmission-based Precautions in the Ambulatory Setting
por: McQuaide, Colleen, et al.
Publicado: (2019)

1202. Subinhibitory Concentrations of Omadacycline Inhibit Staphylococcus aureus Hemolytic Activity in Vitro
por: Serio, Alisa W, et al.
Publicado: (2020)

Causes of Thrombocytosis: A Single-center Retrospective Study of 1,202 Patients
por: Edahiro, Yoko, et al.
Publicado: (2022)

Development of a population pharmacokinetics and pharmacodynamics model of glucarpidase rescue treatment after high-dose methotrexate therapy
por: Fukaya, Yutaka, et al.
Publicado: (2023)

Use of glucarpidase (carboxypeptidase‐G2) in pediatric cancer patients: 11‐year experience of a tertiary center
por: Vila, Rocío, et al.
Publicado: (2023)

Primary intercavernous lymphoma of the central nervous system
por: Dultra, Arthur Henrique de Aquino, et al.
Publicado: (2015)

Central Nervous System Lymphoma Masquerading as Neurosarcoidosis
por: Arakawa, Akira, et al.
Publicado: (2020)

Be mindful of the central nervous system in Burkitt lymphoma
por: Roschewski, Mark
Publicado: (2021)

Insight into resistance mechanism of anaplastic lymphoma kinase to alectinib and JH-VIII-157-02 caused by G1202R solvent front mutation
por: Wang, Han, et al.
Publicado: (2018)

Squash cytology of primary central nervous system lymphoma in an immunocompetent patient
por: Myageri, Aneel, et al.
Publicado: (2013)

1202. Chagas Disease Awareness in a Hispanic Community of the Greater New Orleans Area
por: Hincapie, Marcela, et al.
Publicado: (2021)

P1202: NOVEL METHODS FOR THE IDENTIFICATION OF A RARE DISEASE, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)
por: Broome, Catherine M, et al.
Publicado: (2023)

Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?
por: Matsuo, Toshihiko, et al.
Publicado: (2019)

Isolation and molecular characterization of novel glucarpidases: Enzymes to improve the antibody directed enzyme pro-drug therapy for cancer treatment
por: Rashidi, Fatma B., et al.
Publicado: (2018)

Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study
por: Demiralp, Berna, et al.
Publicado: (2019)

Hypopituitarism and Central Diabetes Insipidus Caused by Central Nervous System Lymphoma
por: Zenimaru, Yasuo, et al.
Publicado: (2018)

Mutational analysis of primary central nervous system lymphoma
por: Bruno, Aurélie, et al.
Publicado: (2014)

Unusual relapse of primary central nervous system lymphoma
por: Igala, Marielle
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pr8osl5p6cagh2r35tcne42tff